Incidence of thromboembolic events in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
J Cancer Res Ther. 2024 Apr 1;20(2):509-521. doi: 10.4103/jcrt.jcrt_1031_23. Epub 2024 Apr 30.ABSTRACTThe incidence of thromboembolic events (TEs) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) has rarely been reported. The MEDLINE, EMBASE, and the Cochrane Library databases were searched. The primary outcome was the incidence of TEs, and the secondary outcome was the relationship between TEs and overall survival (OS) following ICI therapy. A subgroup analysis of TE incidents was performed according to the TE type and combination regimens. The I2 statistic was used to determ...
Source: Cell Research - April 30, 2024 Category: Cytology Authors: Miaomiao Yang Hongxin Cao Congcong Wang Caiyan Yu Ping Sun Source Type: research
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Cancer Res Commun. 2024 Apr 24;4(4):1120-1134. doi: 10.1158/2767-9764.CRC-23-0468.ABSTRACTCombinations of immune checkpoint inhibitors (ICI, including anti-PD-1/PD-L1) and chemotherapy have been FDA approved for metastatic and early-stage triple-negative breast cancer (TNBC), but most patients do not benefit. B7-H4 is a B7 family ligand with proposed immunosuppressive functions being explored as a cancer immunotherapy target and may be associated with anti-PD-L1 resistance. However, little is known about its regulation and effect on immune cell function in breast cancers. We assessed murine and human breast cancer cells to...
Source: Cell Research - April 30, 2024 Category: Cytology Authors: Elizabeth C Wescott Xiaopeng Sun Paula Gonzalez-Ericsson Ann Hanna Brandie C Taylor Violeta Sanchez Juliana Bronzini Susan R Opalenik Melinda E Sanders Julia Wulfkuhle Rosa I Gallagher Henry Gomez Claudine Isaacs Vijaya Bharti John T Wilson Tarah J Ballin Source Type: research
Pharmacological inhibition of HPK1 synergizes with PD-L1 blockade to provoke antitumor immunity against tumors with low antigenicity
Biochem Biophys Res Commun. 2024 Apr 24;715:149995. doi: 10.1016/j.bbrc.2024.149995. Online ahead of print.ABSTRACTImmune checkpoint inhibitors have significantly transformed the landscape of cancer therapy. Nevertheless, while these inhibitors are highly effective for certain patient groups, many do not benefit due to primary or acquired resistance. Specifically, these treatments often lack sufficient therapeutic efficacy against cancers with low antigenicity. Thus, the development of an effective strategy to overcome cancers with low antigenicity is imperative for advancing next-generation cancer immunotherapy. Here, we ...
Source: Cell Research - April 30, 2024 Category: Cytology Authors: Genzui Setsu Megumi Goto Kentaro Ito Tomoe Taira Masaya Miyamoto Tomohiro Watanabe Saito Higuchi Source Type: research
Pharmacological inhibition of HPK1 synergizes with PD-L1 blockade to provoke antitumor immunity against tumors with low antigenicity
Biochem Biophys Res Commun. 2024 Apr 24;715:149995. doi: 10.1016/j.bbrc.2024.149995. Online ahead of print.ABSTRACTImmune checkpoint inhibitors have significantly transformed the landscape of cancer therapy. Nevertheless, while these inhibitors are highly effective for certain patient groups, many do not benefit due to primary or acquired resistance. Specifically, these treatments often lack sufficient therapeutic efficacy against cancers with low antigenicity. Thus, the development of an effective strategy to overcome cancers with low antigenicity is imperative for advancing next-generation cancer immunotherapy. Here, we ...
Source: Biochemical and Biophysical Research communications - April 30, 2024 Category: Biochemistry Authors: Genzui Setsu Megumi Goto Kentaro Ito Tomoe Taira Masaya Miyamoto Tomohiro Watanabe Saito Higuchi Source Type: research
A potassium-chloride co-transporter with altered genome architecture functions as a suppressor in glioma
J Cell Mol Med. 2024 May;28(9):e18352. doi: 10.1111/jcmm.18352.ABSTRACTGliomas, the most lethal tumours in brain, have a poor prognosis despite accepting standard treatment. Limited benefits from current therapies can be attributed to genetic, epigenetic and microenvironmental cues that affect cell programming and drive tumour heterogeneity. Through the analysis of Hi-C data, we identified a potassium-chloride co-transporter SLC12A5 associated with disrupted topologically associating domain which was downregulated in tumour tissues. Multiple independent glioma cohorts were included to analyse the characterization of SLC12A...
Source: J Cell Mol Med - April 30, 2024 Category: Molecular Biology Authors: Hongwei Liu Zhouyang Pan Xuelei Lin Long Chen Qi Yang Wei Zhang Luohuan Dai Yihao Zhang Wang Li Yinhua Chen Kang Peng Siyi Wanggou Feiyue Zeng Xuejun Li Source Type: research
A potassium-chloride co-transporter with altered genome architecture functions as a suppressor in glioma
J Cell Mol Med. 2024 May;28(9):e18352. doi: 10.1111/jcmm.18352.ABSTRACTGliomas, the most lethal tumours in brain, have a poor prognosis despite accepting standard treatment. Limited benefits from current therapies can be attributed to genetic, epigenetic and microenvironmental cues that affect cell programming and drive tumour heterogeneity. Through the analysis of Hi-C data, we identified a potassium-chloride co-transporter SLC12A5 associated with disrupted topologically associating domain which was downregulated in tumour tissues. Multiple independent glioma cohorts were included to analyse the characterization of SLC12A...
Source: Molecular Medicine - April 30, 2024 Category: Molecular Biology Authors: Hongwei Liu Zhouyang Pan Xuelei Lin Long Chen Qi Yang Wei Zhang Luohuan Dai Yihao Zhang Wang Li Yinhua Chen Kang Peng Siyi Wanggou Feiyue Zeng Xuejun Li Source Type: research
The Confounding Role of Graft-Versus-Host Disease in Animal Models of Cancer Immunotherapy: A Systematic Review
CONCLUSION: By systematically identifying and mitigating the confounding effects of GVHD, we can significantly improve the predictive validity of preclinical trials, obtain broadly applicable findings, improve the efficiency of drugs, enhance safety profiling, and develop better therapeutic strategies. This approach is crucial in ensuring that the immunotherapeutic strategies developed in the laboratory are reflective of the human physiological response, thereby bridging a critical translational gap in oncological research.PMID:38685841 | DOI:10.34172/aim.2024.24 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - April 30, 2024 Category: Middle East Health Authors: Hami Ashraf Mohammad Heydarnejad Farid Kosari Source Type: research
Multiomics Analysis of Disulfidptosis Patterns and Integrated Machine Learning to Predict Immunotherapy Response in Lung Adenocarcinoma
CONCLUSION: Our research introduces an innovative prognostic risk model predicated upon disulfidptosis genes for patients afflicted with Lung Adenocarcinoma (LUAD). This model proficiently forecasts the survival rates and therapeutic outcomes for LUAD patients, thereby delineating the high-risk population with distinctive immune cell infiltration and a state of immunosuppression. Furthermore, NAPSA can inhibit the proliferation and invasion capabilities of LUAD cells, thereby identifying new molecules for clinical targeted therapy.PMID:38685772 | DOI:10.2174/0109298673313281240425050032 (Source: Current Medicinal Chemistry)
Source: Current Medicinal Chemistry - April 30, 2024 Category: Chemistry Authors: Junzhi Liu Huimin Li Nannan Zhang Qiuping Dong Zheng Liang Source Type: research
Developing theragnostics for Alzheimer's disease: Insights from cancer treatment
Int J Biol Macromol. 2024 Apr 27:131925. doi: 10.1016/j.ijbiomac.2024.131925. Online ahead of print.ABSTRACTThe prevalence of Alzheimer's disease (AD) and its associated economic and societal burdens are on the rise, but there are no curative treatments for AD. Interestingly, this neurodegenerative disease shares several biological and pathophysiological features with cancer, including cell-cycle dysregulation, angiogenesis, mitochondrial dysfunction, protein misfolding, and DNA damage. However, the genetic factors contributing to the overlap in biological processes between cancer and AD have not been actively studied. In ...
Source: International Journal of Biological Macromolecules - April 30, 2024 Category: Biochemistry Authors: Hyun-Ju Lee Hee-Jeong Choi Yoo Joo Jeong Yoon-Hee Na Jin Tae Hong Ji Min Han Hyang-Sook Hoe Key-Hwan Lim Source Type: research
Enhanced CTLA ‐4 blockade anti‐tumor immunity with APG‐157 combination in a murine head and neck cancer
ConclusionsThe results indicate that APG-157 and immune checkpoint inhibitor combination treatment could potentially lead to improved tumor control. (Source: Cancer Medicine)
Source: Cancer Medicine - April 30, 2024 Category: Cancer & Oncology Authors: Daniel Sanghoon Shin,
Saroj Basak,
Mysore S. Veena,
Bego ña Comin‐Anduix,
Arjun Bhattacharya,
Tien S. Dong,
Albert Ko,
Philip Han,
Jonathan Jacobs,
Neda A. Moatamed,
Luis Avila,
Matteo Pellegrini,
Marilene Wang,
Eri S. Srivatsan Tags: RESEARCH ARTICLE Source Type: research
Implications of intestinal microecology and immune function alterations for immunotherapy outcomes in advanced unresectable lung adenocarcinoma
ConclusionThe structuring of gut flora plays a pivotal role in augmenting the efficacy of anti-tumor immunotherapy, underscoring the interplay between intestinal microecology and immune response in cancer treatment outcomes. (Source: The Clinical Respiratory Journal)
Source: The Clinical Respiratory Journal - April 30, 2024 Category: Respiratory Medicine Authors: Shuang He,
Jin Tian,
Jianhua Zang,
Lin Long,
Peng Liu,
Yexi Zhang,
Jun Xiao Tags: ORIGINAL ARTICLE Source Type: research
Hepatitis B virus reactivation in hepatocellular carcinoma patients after hepatic arterial infusion chemotherapy combined with and without immunotherapy
Hepatitis B virus (HBV) reactivation (HBVr) is a major concern for hepatocellular carcinoma (HCC) patients undergoing hepatic arterial infusion chemotherapy (HAIC) using mFOLFOX6 regimen. There is insufficient... (Source: Infectious Agents and Cancer)
Source: Infectious Agents and Cancer - April 30, 2024 Category: Cancer & Oncology Authors: Lijie Zhang, Yiming Liu, Songlin Song, Joyman Makamure, Heshui Shi, Chuansheng Zheng and Bin Liang Tags: Research Source Type: research
Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer
ConclusionsEnvafolimab yielded promising surgical outcomes and safety in dMMR/MSI-H locally advanced colon cancer, representing a promising treatment modality for this population. (Source: Targeted Oncology)
Source: Targeted Oncology - April 30, 2024 Category: Cancer & Oncology Source Type: research
Biomimetic nanodrug blocks CD73 to inhibit adenosine and boosts antitumor immune response synergically with photothermal stimulation
Combination of tumor immunotherapy with photothermal therapy (PTT) is a feasible tactic to overcome the drawback of immunotherapy such as poor immune response. Via triggering the immunogenic cells death (ICD), PT... (Source: Journal of Nanobiotechnology)
Source: Journal of Nanobiotechnology - April 30, 2024 Category: Nanotechnology Authors: Tan Li, Xingyu Zhang, Chengyu Shi, Qiao Liu and Yuetao Zhao Tags: Research Source Type: research
The association of ROS1 mutation with cancer immunity and its impact on the efficacy of pan-cancer immunotherapy
(Source: Journal of Translational Medicine)
Source: Journal of Translational Medicine - April 30, 2024 Category: Research Authors: Yingying Li, Hong Zhao, Jinyuan Huang, Huimeng Yan and Bin Zhao Tags: Letter to the Editor Source Type: research
